The TB Enigma:cracking the Code with a multifaceted Approach
Tuberculosis (TB) continues to be a significant global health challenge, intensified by drug-resistant forms such as multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB. Despite available treatments, challenges like prolonged therapy, side effects, and delayed diagnosis hinder effective control. Globally, TB remains one of the leading causes of death from a single infectious agent, with an estimated 10.8 million new cases and 1.25 million deaths reported in 2023. Key Developing Countries, notably India, China, and Indonesia, account for a disproportionate share of cases, showcasing the acute necessities in these regions. This review highlights the complex nature of TB infection and the limitations of traditional first- and second-line drugs, emphasizing issues like toxicity and drug interactions. Recent pharmaceutical progress, particularly the approval of novel agents such as Bedaquiline and Delamanid, marks an important step forward in treating resistant TB strains. Cutting-edge drug delivery technologies using nanotechnology and macrophage targeting improve drug stability, bioavailability, and reduce systemic toxicity. Furthermore, plant-based phytochemicals and immunomodulators offer promising adjunctive therapies to enhance immune responses and mitigate treatment side effects. This integrative approach holds the potential to transform TB management and accelerate progress toward the ultimate eradication of this ancient but preventable disease.
Authors
- Varsha Mehra (ORCID: https://orcid.org/0000-0002-8961-7845)
- Gunjan Chalukya (ORCID: https://orcid.org/0009-0004-8551-8569)
- Nisha Prakash (ORCID: https://orcid.org/0009-0003-0864-0571)
Institutions
- University of Delhi (IN)
Publication Details
- Journal
- International Journal of Innovation and Multidisciplinary Research
- Published
- 2026-11-15
- DOI
- https://doi.org/10.67505/ijiamr.v6.i2.62008
- Primary Topic
- Tuberculosis Research and Epidemiology
- Type
- article
- Field-Weighted Citation Impact
- 0.00